Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Angiogenesis. 2010 Dec 28;14(1):61–68. doi: 10.1007/s10456-010-9195-8

Fig. 2.

Fig. 2

Effect of VEGI treatment on peripheral blood EPC (GFP+-Flk-1+-CD133+) and bone marrow HSC (Lin-c-Kit+-Sca-1+) a Fold change of circulating EPC. Blood was collected via tail vein on day 0 prior to tumor inoculation and on days 4, 5, and 6 prior to VEGI treatment (n = 3 per group). Day 7 blood samples collected 24 h after the last treatment. b Percentages of HSC in whole bone marrow on Day 7. Samples analyzed by using flow cytometry